Cargando…

Improving the Gastrointestinal Stability of Linaclotide

[Image: see text] High susceptibility to proteolytic degradation in the gastrointestinal tract limits the therapeutic application of peptide drugs in gastrointestinal disorders. Linaclotide is an orally administered peptide drug for the treatment of irritable bowel syndrome with constipation (IBS-C)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braga Emidio, Nayara, Tran, Hue N. T., Andersson, Asa, Dawson, Philip E., Albericio, Fernando, Vetter, Irina, Muttenthaler, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237258/ https://www.ncbi.nlm.nih.gov/pubmed/33979161 http://dx.doi.org/10.1021/acs.jmedchem.1c00380

Ejemplares similares

On the Utility of Chemical Strategies to Improve Peptide Gut Stability
por: Kremsmayr, Thomas, et al.
Publicado: (2022)

Expanding the versatility and scope of the oxime ligation: rapid bioconjugation to disulfide-rich peptides
por: Hering, Anke, et al.
Publicado: (2022)

Two for the Price of One: Heterobivalent Ligand Design Targeting Two Binding Sites on Voltage-Gated Sodium Channels Slows Ligand Dissociation and Enhances Potency
por: Peschel, Alicia, et al.
Publicado: (2020)

Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions
por: Heuer, Jörn, et al.
Publicado: (2020)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide
por: Qiu, Zhonghao, et al.
Publicado: (2023)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide
por: Busby, Robert W., et al.
Publicado: (2014)

Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
por: Cobos, Claudia, et al.
Publicado: (2018)

Linaclotide utilization and potential for off-label use and misuse in three European countries
por: Cid-Ruzafa, Javier, et al.
Publicado: (2022)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
por: Tchernychev, Boris, et al.
Publicado: (2015)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Semi-synthetic nanobody-ligand conjugates exhibit tunable signaling properties and enhanced transcriptional outputs at neurokinin receptor-1
por: Emidio, Nayara Braga, et al.
Publicado: (2023)

Critical role of down-regulated in adenoma bicarbonate transporter in linaclotide stimulated intestinal bicarbonate secretion
por: Sarthi, Jessica B., et al.
Publicado: (2023)

Strategies for Improving Peptide Stability and Delivery
por: Al Musaimi, Othman, et al.
Publicado: (2022)

A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa
por: Kang, Sang Bum, et al.
Publicado: (2015)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States
por: Nag, Arpita, et al.
Publicado: (2020)

The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review
por: Baaleman, Desiree F., et al.
Publicado: (2021)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
por: Serrano-Falcón, Blanca, et al.
Publicado: (2019)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis
por: Rao, Satish S.C., et al.
Publicado: (2020)

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Linaclotide activates guanylate cyclase‐C/cGMP/protein kinase‐II‐dependent trafficking of CFTR in the intestine
por: Ahsan, Md. Kaimul, et al.
Publicado: (2017)

Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis
por: Yang, Jiao, et al.
Publicado: (2021)

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
por: Lacy, B E, et al.
Publicado: (2014)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors
por: Cuppoletti, John, et al.
Publicado: (2012)

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China
por: Liu, Lan, et al.
Publicado: (2022)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Approaches to Improve the Quantitation of Oxytocin in Human Serum by Mass Spectrometry
por: Hering, Anke, et al.
Publicado: (2022)

Bowel preparation efficacy and safety of compound polyethylene glycol electrolyte powder combined with linaclotide for colonoscopy: A randomized controlled trial
por: Yang, Jing, et al.
Publicado: (2023)

Structural and functional insights into the inhibition of human voltage-gated sodium channels by μ-conotoxin KIIIA disulfide isomers
por: Tran, Hue N.T., et al.
Publicado: (2022)

Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study
por: Pohl, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e7um1h27ap65sbchavooter9i7